The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma

B. S. Hoppe, Craig Moskowitz, Z. Zhang, J. C. Maragulia, R. D. Rice, A. S. Reiner, P. A. Hamlin, A. D. Zelenetz, J. Yahalom

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

We examined the role of fluorodeoxyglucose-positron emission tomography (FDG-PET) and the addition of involved field radiotherapy (IFRT) as potential modifiers of salvage therapy. From January 2000 to June 2007, 83 patients with chemosensitive relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL) underwent FDG-PET scans following second-line chemotherapy before high-dose therapy with autologous stem cell rescue (HDT/ASCR). We evaluated the prognostic value of having a negative FDG-PET scan before HDT/ASCR and whether IFRT improved the outcomes. Median follow-up was 45 months, and the 3-year PFS, disease-specific survival (DSS) and OS were 72, 80 and 78%, respectively. Multivariate analysis revealed that a positive FDG-PET scan had worse PFS (hazard ratio = (HR) 3.4; P = 0.014), DSS (HR = 7.7; P = 0.001) and OS (HR = 5.4; P = 0.001), and that patients not receiving IFRT had worse PFS (HR = 2.7; P = 0.03) and DSS (HR = 2.8, P = 0.059). Patients who received IFRT had better local control with fewer relapses within prior involved sites compared with those that did not receive IFRT (P = 0.006). These outcomes confirm the important prognostic value of FDG-PET scans before undergoing HDT/ASCR. It also suggests that the role of IFRT should be evaluated further.

Original languageEnglish (US)
Pages (from-to)941-948
Number of pages8
JournalBone Marrow Transplantation
Volume43
Issue number12
DOIs
StatePublished - Jan 13 2009
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Hoppe, B. S., Moskowitz, C., Zhang, Z., Maragulia, J. C., Rice, R. D., Reiner, A. S., Hamlin, P. A., Zelenetz, A. D., & Yahalom, J. (2009). The role of FDG-PET imaging and involved field radiotherapy in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transplantation, 43(12), 941-948. https://doi.org/10.1038/bmt.2008.408